Li-ping Ge

270 Dong An Road
Shanghai, 200032, China

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 13 publications

Current and future therapies for triple-negative breast cancer.

Current and future therapies for triple-negative breast cancer.

Journal: Journal of hematology & oncology
Published: May 04, 2026

Precision treatment with artificial intelligence assisted subtyping enhances therapeutic efficacy in HR+/HER2- breast cancer: The LINUXtrial.

Precision treatment with artificial intelligence assisted subtyping enhances therapeutic efficacy in HR+/HER2- breast cancer: The LINUXtrial.

Journal: Cancer cell
Published: March 08, 2025

Combination of autophagy inhibitors with high-dose CDK4/6 inhibitors offers new hope for advanced HR+/HER2- breast cancer.

Combination of autophagy inhibitors with high-dose CDK4/6 inhibitors offers new hope for advanced HR+/HER2- breast cancer.

Journal: Med (New York, N.Y.)
Published: December 15, 2024

CXCR6 expression predicts prognosis and immunotherapeutic benefit in muscle-invasive bladder cancer.

CXCR6 expression predicts prognosis and immunotherapeutic benefit in muscle-invasive bladder cancer.

Journal: Frontiers in oncology
Published: September 19, 2024

Psychological Stress and Its Correlations to Patients with Acute Lymphedema After Breast Cancer Surgery.

Psychological Stress and Its Correlations to Patients with Acute Lymphedema After Breast Cancer Surgery.

Journal: Breast cancer (Dove Medical Press)
Published: August 15, 2024

Targeting transposable elements in cancer: developments and opportunities.

Targeting transposable elements in cancer: developments and opportunities.

Journal: Biochimica et biophysica acta. Reviews on cancer
Published: December 07, 2023

ZNF689 deficiency promotes intratumor heterogeneity and immunotherapy resistance in triple-negative breast cancer.

ZNF689 deficiency promotes intratumor heterogeneity and immunotherapy resistance in triple-negative breast cancer.

Journal: Cell research
Published: February 26, 2023

DNAzyme-based faithful probing and pulldown to identify candidate biomarkers of low abundance.

DNAzyme-based faithful probing and pulldown to identify candidate biomarkers of low abundance.

Journal: Nature chemistry
Published: December 22, 2022

Comprehensive metabolomics expands precision medicine for triple-negative breast cancer.

Comprehensive metabolomics expands precision medicine for triple-negative breast cancer.

Journal: Cell research
Published: May 07, 2021

Randomized phase II clinical trial and biomarker analysis of paclitaxel plus epirubicin versus vinorelbine plus epirubicin as neoadjuvant chemotherapy in locally advanced HER2-negative breast cancer with TEKT4 variations.

Randomized phase II clinical trial and biomarker analysis of paclitaxel plus epirubicin versus vinorelbine plus epirubicin as neoadjuvant chemotherapy in locally advanced HER2-negative breast cancer with TEKT4 variations.

Journal: Breast cancer research and treatment
Published: July 08, 2020

SYTL4 downregulates microtubule stability and confers paclitaxel resistance in triple-negative breast cancer.

SYTL4 downregulates microtubule stability and confers paclitaxel resistance in triple-negative breast cancer.

Journal: Theranostics
Published: February 22, 2020

LncRNA TROJAN promotes proliferation and resistance to CDK4/6 inhibitor via CDK2 transcriptional activation in ER+ breast cancer.

LncRNA TROJAN promotes proliferation and resistance to CDK4/6 inhibitor via CDK2 transcriptional activation in ER+ breast cancer.

Journal: Molecular cancer
Published: December 02, 2019
Showing 1-12 of 13

Last Updated: 09/26/2026